Eukedos S.p.A. (IT:EUK)
:EUK
Want to see IT:EUK full AI Analyst Report?
Top Page
Eukedos S.p.A.
(EUK)
Select Model
Select Model
Rating:44Neutral
Price Target:
€0.58
▼(-19.86% Downside)
Action:Reiterated
Date:06/09/26
The score is primarily constrained by financial risk: very high leverage and a shift to net losses in 2024–2025, despite steady operating margins and positive operating cash flow. Technically, the stock is below major moving averages, signaling a weaker trend, while valuation is difficult to support with a negative P/E and no dividend yield data.
Positive Factors
Contractual, fee-based business model
Eukedos’s core revenue comes from contracted service fees and public/private reimbursements, creating structurally recurring cash flows tied to care delivery demand. This business model provides revenue predictability and demand insulation from cyclical industries given aging populations and long-term care needs.
Negative Factors
Very high leverage
Extremely high debt relative to equity materially reduces financial flexibility and heightens interest-rate and refinancing vulnerability. With a small equity cushion, even modest operational setbacks could strain covenants or force costly refinancing, constraining capital allocation and strategic options over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Contractual, fee-based business model
Eukedos’s core revenue comes from contracted service fees and public/private reimbursements, creating structurally recurring cash flows tied to care delivery demand. This business model provides revenue predictability and demand insulation from cyclical industries given aging populations and long-term care needs.
Read all positive factors
Eukedos S.p.A. (EUK) vs. iShares MSCI Italy ETF (EWI)
Market Cap
€14.90M
Dividend YieldN/A
Average Volume (3M)4.68K
Price to Earnings (P/E)―
Beta (1Y)0.34
Revenue Growth2.31%
EPS Growth-43.04%
CountryIT
Employees483
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)N/A
Shares Outstanding22,741,629
10 Day Avg. Volume3,064
30 Day Avg. Volume4,678
Financial Highlights & Ratios
PEG Ratio-0.50
Price to Book (P/B)0.55
Price to Sales (P/S)0.31
P/FCF Ratio36.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Eukedos S.p.A. Business Overview & Revenue Model
Company Description
EuKedos S.p.A. operates in Italy, offering a range of managed and long-term care provisions. The company specializes in delivering residential social support for older adults, catering to both independent individuals and those needing extensive as...
How the Company Makes Money
Eukedos makes money primarily by providing social and healthcare services and being paid for the management and delivery of those services (e.g., operating care facilities and/or providing care-related services under contractual arrangements). Rev...
Eukedos S.p.A. Financial Statement Overview
Summary
Income Statement
48
Neutral
Balance Sheet
29
Negative
Cash Flow
41
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 51.64M | 51.69M | 49.45M | 47.04M | 45.18M |
| Gross Profit | 12.09M | 48.96M | 13.73M | 32.03M | 32.99M |
| EBITDA | 10.26M | 12.27M | 12.41M | 10.87M | 10.72M |
| Net Income | -749.00K | -524.00K | 556.00K | 443.00K | 570.00K |
Balance Sheet | |||||
| Total Assets | 180.33M | 179.34M | 149.10M | 153.38M | 150.08M |
| Cash, Cash Equivalents and Short-Term Investments | 416.00K | 3.91M | 2.33M | 3.62M | 7.39M |
| Total Debt | 128.29M | 99.02M | 105.83M | 111.45M | 108.95M |
| Total Liabilities | 151.23M | 149.50M | 119.19M | 123.99M | 121.26M |
| Stockholders Equity | 29.10M | 29.84M | 29.91M | 29.39M | 28.82M |
Cash Flow | |||||
| Free Cash Flow | 436.00K | -13.14M | 3.59M | 1.03M | 5.31M |
| Operating Cash Flow | 6.24M | 9.94M | 10.08M | 5.18M | 5.61M |
| Investing Cash Flow | -5.86M | -58.49M | -8.92M | -4.15M | -306.00K |
| Financing Cash Flow | -3.87M | 50.13M | -2.45M | -4.79M | -562.00K |
Eukedos S.p.A. Technical Analysis
Positive
0.72
Price Trends
0.63
Positive
0.64
Positive
0.68
Negative
Market Momentum
<0.01
Negative
53.39
Neutral
60.87
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:EUK, the sentiment is Positive. The current price of 0.72 is above the 20-day moving average (MA) of 0.64, above the 50-day MA of 0.63, and above the 200-day MA of 0.68, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 53.39 is Neutral, neither overbought nor oversold. The STOCH value of 60.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IT:EUK.
Eukedos S.p.A. Peers Comparison
UnderperformOutperform
Sector (51)
IT:EUK
Eukedos S.p.A.
0.66
-0.15
-18.13%
IT:ARBS
Arterra Bioscience SpA
2.83
0.60
27.13%
IT:COSMO
Farmacosmo S.P.A.
0.39
-0.18
-31.58%
IT:TALEA
Farmae SpA
4.80
0.25
5.49%
IT:ERFO
Laboratorio Farmaceutico Erfo SpA
1.09
-0.15
-12.10%
IT:SVS
Svas Biosana S.p.A.
9.74
2.09
27.37%
Eukedos S.p.A. Corporate Events
Eukedos Board Member Resigns; Company to Co-Opt Successor to Meet Gender Parity Rules
May 7, 2026
Eukedos has announced the resignation of non-executive board member Barbara Maiani, effective 30 April 2026, citing personal reasons, with the company expressing appreciation for her service. The outgoing director was not independent, held no shar...
Eukedos Shareholders Back 2025 Accounts Under Dominant La Villa Control
May 4, 2026
Eukedos S.p.A. reported that its ordinary shareholders’ meeting on 29 April 2026 was dominated by majority owner La Villa S.p.A., which was represented by proxy for 20,465,527 shares, equal to 89.991% of the company’s ordinary share ca...
Eukedos Shareholders Approve 2025 Results and 2026 Remuneration Policy
Apr 29, 2026
Eukedos S.p.A. reported its 2025 consolidated production value at €52.907 million, with a gross operating margin of €11.154 million and a net operating margin of €5.403 million, while the parent company booked a loss of €21...
Eukedos Publishes 2025 Annual Report and Governance Documents Ahead of April Shareholder Meeting
Apr 7, 2026
Eukedos S.p.A. has published its Annual Financial Report for the year ended 31 December 2025, including separate and consolidated financial statements, the management report, and accompanying auditors’ and statutory auditors’ reports. ...
Eukedos edges up revenues in 2025 but widens net loss amid high debt
Mar 30, 2026
Eukedos S.p.A. has approved its 2025 draft separate and consolidated financial statements, reporting a consolidated value of production of €52.9 million, up from €51.6 million a year earlier, driven mainly by the Care Area’s 2.1%...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.